For these patients, semaglutide offers a clinically proven way to reduce weight and lower the risk of related conditions such as cardiovascular disease, sleep apnea, and joint problems
Its remarkably early for any kind of prime-time clinical consideration, Goodman said
This puts them at increased risk of death and many serious health issues, but losing weight and keeping it off through diet changes and exercise the standard approach is notoriously difficult
In that context, NAD IV therapy should be planned around the full medication list, current energy levels, and provider guidance rather than treated as a default add-on
Judith Bray, vice-president of research at the Canadian Cancer Society, said that the research has the potential to be transformative. These rumbling or smoking guns have been firing off for well over a year now about this possibility, she said